Business Wire

Prophylaxis to COVID-19 by AFO-202 ß-Glucan Food Supplement From Japan

Share

Caucasian, Hispanic and Afro-American population, when Covid-19 infected, are prone to abnormal blood clotting, that may lead to stroke. Pregnant women and people with comorbidities are also at high risk. Higher mortality has been reported in patients, whose fasting plasma glucose is very high at the time of hospital admission with SARS-COV-2. During this unprecedented pandemic, a prophylaxis to Covid-19 in diabetic population, and strategies for Prevention of Covid-19 associated coagulopathy by consumption of Beta glucan food supplement produced by Black yeast Aureobasidium Pullulans AFO-202 strain has been published in Journal of Diabetes and Metabolic Disorders (https://doi.org/10.1007/s40200-020-00664-4) and Thrombosis Journal (https://doi.org/10.1186/s12959-020-00239-6) respectively, recommending clinical studies for its validation in Covid-19 patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201025005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Salient features of AFO-202 secreted Nichi-Glucan on its potentials of prophylaxis to Covid-19 related complications through Blood glucose, cholesterol and coagulation system balancing. (Graphic: Business Wire)

COVID-19 virus damages blood vessels, causing clot or thrombus formation resulting in stroke and disruption of the body’s blood clotting system, leading to organ damage and death. Metabolic and immune dysregulation leads to higher mortality in diabetes patients. The AFO-202 derived Nichi-Glucan has potentials to alleviate the cytokine storm, minimize coagulation disruption, and prevent complications of Covid-19 by balancing blood glucose & cholesterol, according to the authors, who have earlier published its immune enhancement and modulation capabilities to help tackle Covid-19 (https://doi.org/10.3389/fimmu.2020.01548). Pilot studies in Diabetic and Dyslipidemic individuals from south Asian population also have been reported (https://doi.org/10.1155/2012/895370).

Unique advantages: Research of Prof. Noboru Fujii on poly-thermo tolerant fungi lead to the successful culture of Aureobasidium Pullulans and Mr. Takashi Onaka (President, Sophy Inc) accomplished its industrial scale GMP production in Kochi, Japan, which was approved by Japanese health ministry as a food additive and in the market since 1996. Among several ß-Glucans produced by extraction and purification methods from sources like yeast-cell wall, Shiitake mushroom, Oats, Algae etc, Nichi Glucan is unique, being secreted as an exo-polysaccharide by AFO-202, possessing a distinct structure, water solubility, high purity, functionality and molecular weight of 30,000. Safety has been confirmed by genotoxicity, repeated and long-term administration tests. Recently, a new strain, N-163 secreted product, having advantageous characteristics to contribute to human health is undergoing studies. Nichi Glucan is available in Japan (www.nichiglucan.com) and in India (https://www.amazon.in/dp/B08DFDX2HQ), exported worldwide by GN Corporation.

Disclaimer: Nichi-Glucan is a food supplement, free from 25 most common allergens. It’s not a drug or curative/therapeutic agent.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GN Corporation Co, Ltd
Samuel JK Abraham
info@gncorporation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member10.5.2024 18:45:00 EEST | Press release

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity. Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells. As we advance toward the clinical development of EGL-001, John’s expertise in business development in the field of oncology is instrumental for us to successfully execute on our strategic priorities.” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member. “I am excited to join Egle Therapeutics to translate into the c

HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row10.5.2024 17:00:00 EEST | Press release

HighRadius, the leading provider of the Autonomous Finance Platform for the office of the CFO, has once again been named a Leader in the 2024 Gartner Magic Quadrant for Invoice-to-Cash Applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510668572/en/ HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row (Graphic: Business Wire) Gartner Magic Quadrant gives enterprise technology shoppers an unbiased assessment of how well-competing providers are performing against Gartner’s market view and is supplemented by validated user reviews. According to Gartner, “Leaders execute well against their current vision and are well positioned for tomorrow.” This is the third consecutive year for HighRadius to be placed as a leader on the report. “We're honored to be recognized for our maniacal focus on invoice-to-cash business outcome improvements - DSO, Bad Debt, Interchange Fees, & Productivity,” sai

The Ministry of Investment of Saudi Arabia (MISA) Signs MoU with Ant International to Expand Business in Saudi Arabia, Supporting Regional Digital Innovation10.5.2024 16:36:00 EEST | Press release

The Ministry of Investment of Saudi Arabia (MISA) has signed a Memorandum of Understanding (MoU) with Ant International, to facilitate the business expansion into the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507130337/en/ (Photo: Business Wire) Ant International’s President, Douglas Feagin, met with Mr. Eng Saleh Khabti, Deputy Minister of Investment of Saudi Arabia during a signing ceremony held in Riyadh, to welcome the new partnership and sign an agreement outlining shared goals for technological innovation and economic growth opportunities in Saudi Arabia. Through this partnership, MISA welcomes and supports Ant International’s expansion plan to establish an entity in Saudi Arabia, enabling assistance when acquiring licences and certificates to expand and enhance its service offerings. Ant International will use Saudi Arabia as a key gateway into the Middle East to further expand the reach of its paymen

Wipro Appoints Vinay Firake as Chief Executive Officer for APMEA Strategic Market Unit10.5.2024 16:11:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Vinay Firake as the Chief Executive Officer, APMEA (Asia Pacific, India, Middle East & Africa) Strategic Market Unit (SMU), effective immediately. Vinay will report to Srini Pallia and will also join the Wipro Executive Board. Vinay has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Senior Vice President and Managing Director of Wipro-Nordics Business Unit based in Stockholm, where he led Operations across all industries and services. Prior to that, he led the Manufacturing & Automotive Business Unit in Europe and held various roles spanning Europe and North America, including Global Head for the Enterprise Digital Operations & Platforms business and Sales Head for Wipro's Enterprise Applications businesses in Europe. “Vinay has successfully led Wipro in diverse regio

Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D10.5.2024 16:00:00 EEST | Press release

Kolmar BNH (KOSDAQ: 200130), a manufacturer of HemoHIM, a health-enhancing functional food, has emerged as a frontrunner in the global Original Development Manufacturing (ODM) market, owing to its pioneering investments in research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510895890/en/ A researcher from Kolmar BNH Health Food Lab. (Photo: Kolmar BNH) Founded in 2005, Kolmar BNH is an ODM company for health-functional food products. ODM enterprises, encompassing various sectors from trend analysis to R&D, product conceptualization, manufacturing, and quality assurance, cater to customers with entrepreneurial aspirations. This framework facilitates opportunities for individuals with a passion for business and ideas. The cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments. The company annually allocates over 2% of its sales revenue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye